Raloxifene: Risks and Benefits

  title={Raloxifene: Risks and Benefits},
  author={Elizabeth Barrett-Connor},
  journal={Annals of the New York Academy of Sciences},
  • E. Barrett-Connor
  • Published 1 December 2001
  • Medicine
  • Annals of the New York Academy of Sciences
Abstract: Raloxifene, a selective estrogen receptor modulator (SERM), was designed to have the expected benefits of long‐term estrogen replacement therapy without the risks. This paper reviews the clinical trial evidence for raloxifene benefits and risks, and how they compare with those of hormone replacement therapy (HRT) and relate to the choices of postmenopausal women. 

Selective estrogen receptor modulators: tissue actions and potential for CNS protection.

This review focuses on the CNS and known neuroprotective effects of two specific SERMs, raloxifenes and arzoxifene, and suggests that ralOXifene and arZoxIfene are neuroprot protective and may preserve some elements of cognitive function.

Prevention of hormone-related cancers: breast cancer.

  • B. DunnD. WickerhamL. Ford
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
Based on promising data involving reduction of contralateral breast cancer risk in adjuvant studies, several aromatase inhibitors are being incorporated into trials evaluating their efficacy as preventive agents in women at increased risk.

Oestrogen receptors and linear bone growth

It is concluded that SERMs potentially could offer new possibilities to modulate bone growth by specifically targeting different oestrogen receptors within the growth plate.

Hormonal interventions to prevent hormonal cancers: breast and prostate cancers

  • B. DunnL. Ford
  • Medicine
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation
  • 2007
In an effort to improve its benefit–risk profile, tamoxifen is now being compared with raloxifene, a selective estrogen receptor modulator approved for the treatment and prevention of osteoporosis, which shows efficacy in breast cancer adjuvant trials.

Raloxifene acts as an estrogen agonist on the rabbit growth plate.

It is concluded that raloxifene acts as an estrogen agonist on the growth plate, accelerating growth plate senescence and thus hastening epiphyseal fusion.

[Estrogen intracrinology: therapy and chemoprevention of breast cancer].

Key enzymes in estrogen's biosynthesis in the breast and their potential use in therapy and chemoprevention of breast carcinoma are discussed.

Breast cancer and post-menopausal hormone therapy.

  • P. KenemansA. Bosman
  • Medicine, Biology
    Best practice & research. Clinical endocrinology & metabolism
  • 2003



Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.

Raloxifene favorably alters biochemical markers of cardiovascular risk by decreasing LDL-C, fibrinogen, and lipoprotein(a), and by increasing HDL2-C without raising triglycerides.

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study.

It is suggested that in healthy postmenopausal women, raloxifene and estrogen monotherapy have similar beneficial effects on low density lipoprotein cholesterol and fibrinogen levels.

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial

Tamoxifen citrate, which inhibits the action of estrogen on breast tissue, improves disease-free survival among women who have estrogen receptor, and raloxifene hydrochloride is a selective estrogen receptor modulator that has antiestrogenic effects on breast and endometrial tissue and estrogenIC effects on bone, lipid metabolism, and blood clotting.

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

Among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during 3 years of treatment with raloxifene, mainly in the United States and Europe.

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

Daily therapy with raloxifene increases bone mineral density, lowers serum concentrations of total and low-density lipoprotein cholesterol, and does not stimulate the endometrium.

Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial

It is indicated that raloxifene treatment over 3 years not only preserves bone mass but also lowers the risk of new vertebral fractures in postmenopausal women with osteoporosis, regardless of whether they have had fractures before starting treatment.

A clinical trial of estrogen-replacement therapy after ischemic stroke.

Estradiol does not reduce mortality or the recurrence of stroke in postmenopausal women with cerebrovascular disease and this therapy should not be prescribed for the secondary prevention of cerebroVascular disease.